Skip to main content
SpringerLink
Log in

Réduction tumorale différée après chimiothérapie néo-adjuvante

  • Chapter
Les cancers ovariens

Part of the book series: Abord clinique ((ONCOLPRAT))

  • 324 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Neijt JP, Aartsen EJ, Bouma J et al. (1985) Cytoreductive surgery with or without preceding chemotherapy in ovarian cancer. Prog Clin Biol Res 201: 217–23

    CAS  PubMed  Google Scholar 

  2. Wils J, Blijham G, Naus A et al. (1986) Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 4: 1068–73

    CAS  PubMed  Google Scholar 

  3. Lawton FG, Redman CWE, Luesley DM et al. (1989) Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstet Gynecol 73: 61–5

    CAS  PubMed  Google Scholar 

  4. Jacob JH, Gershenson DM, Morris M et al. (1991) Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian carcinoma. Gynecol Oncol 42: 146–50

    Article  CAS  PubMed  Google Scholar 

  5. Vergote I, De Wever I, Tjalma W et al. (2000) Interval debulking surgery: an alternative for primary surgical debulking? Sem Surg Oncol 19: 49–53

    CAS  Google Scholar 

  6. Lim JTW, Green JA (1993) Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol 5: 198–202

    Article  CAS  Google Scholar 

  7. Surwit E, Childers J, Atlas I et al. (1996) Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynaecol Cancer 6: 356–61

    Google Scholar 

  8. Vergote I, De Wever I, Tjalma W et al. (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 71: 431–6

    Article  CAS  PubMed  Google Scholar 

  9. Tate S, Hairai Y, Takeshima N et al. (2005) CA 125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian adenocarcinoma. Gynecol Oncol 96: 143–9

    Article  CAS  PubMed  Google Scholar 

  10. Recchia F, de Filippis S, Rosseli M et al. (2001) Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaec Oncol 22: 287–91

    CAS  Google Scholar 

  11. Ansquer Y, Leblanc E, Clough K et al. (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 91: 2329–34

    Article  CAS  PubMed  Google Scholar 

  12. Mazzeo F, Berlière M, Kerger J et al. (2003) Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90: 163–9

    Article  CAS  PubMed  Google Scholar 

  13. Le T, Faught W, Hopkins L et al. (2005) Primary chemotherapy and adjuvant tumour debulking in the management of advanced staged epithelial ovarian cancer. Communication personnelle, soumis Int J Gynecol Cancer

    Google Scholar 

  14. Schwartz PE, Chambers JT, Makuch R (1994) Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 53: 33–7

    Article  CAS  PubMed  Google Scholar 

  15. Neijt JP, ten Bokkel Huinink WW, van der Burg ME et al. (1991) Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27: 1367–72

    CAS  PubMed  Google Scholar 

  16. Morice P, Brehier-Ollive D, Rey A et al. (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non exposed study; Ann Oncol 14: 74–7

    CAS  PubMed  Google Scholar 

  17. Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–59

    Article  PubMed  Google Scholar 

  18. Griffiths CT, Parker LM, Fuller AF (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63: 235–40

    CAS  PubMed  Google Scholar 

  19. Onnis A, Marchetti M, Padovan P et al. (1996) Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 17: 393–6

    CAS  PubMed  Google Scholar 

  20. Schwartz PE, Rutherford TJ, Chambers JT et al. (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: long term survival. Gynecol Oncol 72: 93–9

    Article  CAS  PubMed  Google Scholar 

  21. Shibata K, Kikkawa F, Mika M et al. (2003) Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: survival benefit and prognostic factors. Int J Gynecol Cancer 13: 587–92

    Article  CAS  PubMed  Google Scholar 

  22. Ushijima K, Ota S, Komai K et al. (2002) Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer Int Surg 87: 185–90

    Google Scholar 

  23. Kayikçiog Lu F, Köse MF, Boran N et al. (2001) Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11: 466–70

    Google Scholar 

  24. Ursic Vrscaj M, Rakar S (2002) Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol 23: 405–10

    PubMed  Google Scholar 

  25. Deval B, Paitel JF, Platini C et al. (2003) Surgery (S): an option for patients with FIGO stage IV ovarian cancer (OC) treated by platinum-paclitaxel-based regimen? A GINECO study. ASCO meeting: abstract 1817

    Google Scholar 

  26. Kuhn W, Rutke S, Späthe K et al. (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obxtetrics stage IIIC ovarian carcinoma. Cancer 92: 2585–91

    Article  CAS  PubMed  Google Scholar 

  27. Morice P, Dubernard G, Rey A et al. (2003) Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 197: 955–63

    PubMed  Google Scholar 

  28. Redman C, Warwick J, Luesley D et al. (1994) Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 101: 142–6

    CAS  PubMed  Google Scholar 

  29. Van der Burg M, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–34

    PubMed  Google Scholar 

  30. Rose PG, Nerenstone S, Brady MF et al. (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–97

    Article  CAS  PubMed  Google Scholar 

  31. Eisenkop SM, Spirtos NM, Montag TW et al. (1992) The impact of subspeciality training on the management of advanced ovarian cancer. Gynecol Oncol 47: 203–9

    Article  CAS  PubMed  Google Scholar 

  32. Junor E, Hole D, McNulty L et al. (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a scottish national study of 1866 patients. Br J Obstet Gynaecol 19: 273–8

    Google Scholar 

  33. Van der Burg ME, Van Lent M, Kobierska A et al. (2002) Interval debulking surgery significantly increases the survival and progression-free survival in advanced epithelial ovarian cancer patients: an EORTC Gynaecologic Cancer Co-operative Group study. Int Jacobs IJ, Shephard JH et al (Ed). Ovarian Cancer. Oxford University Press, Oxford 299–303

    Google Scholar 

  34. Stoeckle E, Paravis P, Floquet A et al. (2004) Number of residual nodules, better than size, defines optimal surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer 14: 779–87

    Article  CAS  PubMed  Google Scholar 

  35. Chan YM, Ng TY, Ngan YS et al. (2002) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88: 9–16

    Google Scholar 

  36. Covers AL (2000) A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 78: 269–74

    Google Scholar 

Download references

Authors
  1. E. Stoeckle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Floquet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Stoeckle, E., Floquet, A. (2006). Réduction tumorale différée après chimiothérapie néo-adjuvante. In: Les cancers ovariens. Abord clinique. Springer, Paris. https://doi.org/10.1007/2-287-30921-7_18

Download citation

  • DOI: https://doi.org/10.1007/2-287-30921-7_18

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-25168-9

  • Online ISBN: 978-2-287-30921-2

Publish with us

Policies and ethics

Search

Navigation